Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
作者： E. Van Cutsem , A. Cervantes , B. Nordlinger , D. Arnold
关键词:
摘要: E. Van Cutsem1, A. Cervantes2, B. Nordlinger3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Digestive Oncology, University Hospitals Leuven, Belgium; Department Hematology and Medical INCLIVA, Valencia, Spain; General Surgery Surgical Hopital Ambroise Pare, Assistance Publique – Hopitaux de Paris, France; Klinik fur Tumorbiologie, Freiburg, Germany
annalsofoncology.org
oxfordjournals.org
core.ac.uk
oup.com
paperity.org参考文章(64)
Carsten Bokemeyer, Claus-Henning Kohne, Fortunato Ciardiello, Heinz-Josef Lenz, Volker Heinemann, Ute Klinkhardt, Frank Beier, Klaus Duecker, Sabine Tejpar, Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. Journal of Clinical Oncology. ,vol. 32, pp. 3505- 3505 ,(2014) , 10.1200/JCO.2013.31.15_SUPPL.3537
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Juergen Lerchenmueller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Joerg Hielscher, Michael Scholz, Sebastian Mueller, Britta Schaefer, Dominik Paul Modest, Andreas Jung, Sebastian Stintzing, Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA3506
Dirk Arnold, Ullrich Graeven, Christian A. Lerchenmuller, Brigitta Killing, Reinhard Depenbusch, Claus-Christoph Steffens, Salah-Eddin Al-Batran, Thoralf Lange, Georg Dietrich, Jan Stoehlmacher, Andrea Tannapfel, Hans-Joachim Schmoll, Anke Reinacher-Schick, Susanna Hegewisch-Becker, Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). Journal of Clinical Oncology. ,vol. 32, pp. 3503- 3503 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.3503
C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes, H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology. ,vol. 23, pp. 2479- 2516 ,(2012) , 10.1093/ANNONC/MDS236
Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2
Fairooz Kabbinavar, Cornelia Irl, Alfredo Zurlo, Herbert Hurwitz, Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk Oncology. ,vol. 75, pp. 215- 223 ,(2008) , 10.1159/000163850
J. Li, S. Qin, T. Yau, B. Ma, H. Pan, J. Xu, Y. Bai, Y. Chi, L. Wang, K.H. Yeh, F. Bi, Y. Cheng, A.T. Le, J.K. Lin, T. Liu, D. Ma, C. Kappeler, J. Kalmus, R.H. Xu, T.W. Kim, O-0023CONCUR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REGORAFENIB MONOTHERAPY IN ASIAN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (MCRC) Annals of Oncology. ,vol. 25, ,(2014) , 10.1093/ANNONC/MDU193.23
Eric Van Cutsem, Bernard Nordlinger, Rene Adam, Claus-Henning Köhne, Carmelo Pozzo, Graeme Poston, Marc Ychou, Philippe Rougier, None, Towards a pan-European consensus on the treatment of patients with colorectal liver metastases European Journal of Cancer. ,vol. 42, pp. 2212- 2221 ,(2006) , 10.1016/J.EJCA.2006.04.012
Michel Ducreux, David Malka, Jean Mendiboure, Pierre-Luc Etienne, Patrick Texereau, Dominique Auby, Philippe Rougier, Mohamed Gasmi, Marine Castaing, Moncef Abbas, Pierre Michel, Dany Gargot, Ahmed Azzedine, Catherine Lombard-Bohas, Patrick Geoffroy, Bernard Denis, Jean-Pierre Pignon, Laurent Bedenne, Olivier Bouché, Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial Lancet Oncology. ,vol. 12, pp. 1032- 1044 ,(2011) , 10.1016/S1470-2045(11)70199-1
Bernard Nordlinger, Eric Van Cutsem, Philippe Rougier, Claus-Henning Köhne, Marc Ychou, Alberto Sobrero, Rene Adam, Dag Arvidsson, Alfredo Carrato, Vassilis Georgoulias, Felice Giuliante, Bengt Glimelius, Markus Golling, Thomas Gruenberger, Josep Tabernero, Harpreet Wasan, Graeme Poston, None, Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group European Journal of Cancer. ,vol. 43, pp. 2037- 2045 ,(2007) , 10.1016/J.EJCA.2007.07.017